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Introduction
Clinical studies using chimeric antigen receptor (CAR)-modified T-cells or targeted monoclonal antibodies have shown the efficacy of immunotherapy to treat different hematological malignancies. The adoptive transfer of T-cells modified to express CD19targeted CARs have led to complete remissions in patients suffering from chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) [1] [2] [3] [4] . Due to its high expression on malignant cells, CD19 can be efficiently targeted by CAR-transduced Tcells. Similarly, CD20-targeting therapeutic monoclonal antibodies such as Rituximab have caused complete remissions in patients treated for follicular lymphoma 5, 6 and diffuse large B-cell lymphoma 7, 8 in combination with chemotherapy. Besides on malignant B-cells, CD19 and CD20 are also highly expressed on healthy B-cells causing depletion of the B-cell compartment in patients treated with CD19-targeted or CD20targeted immunotherapies 1, [3] [4] [5] 9 . However, side effects of long-term B-cell depletion are manageable which indicates that B-cell aplasia can be tolerated [9] [10] [11] [12] [13] .
Although successful in several patients, malignancies refractory to CD20-targeted therapy and the emergence of CD19-negative tumor escape variants after treatment with CD19-targeting CAR-transduced T-cells 4 demonstrate the need to identify additional targets for the treatment of B-lineage malignancies. We hypothesized that the B-cell receptor (BCR) associated protein CD79b presents a suitable target for immunotherapy since CD79b membrane expression is restricted to the B-cell compartment and can be found on many B-cell malignancies [14] [15] [16] . The BCR associated heterodimer CD79a/b is critically involved in BCR transport 17 and functionality by providing signaling capacity [18] [19] [20] [21] [22] to regulate processes such as allelic exclusion, proliferation, differentiation, anergy and apoptosis [23] [24] [25] . CD79b is encoded by gene B29 26 and through the event of alternative splicing can produce different transcripts 27 . The truncated variant of CD79b, missing For personal use only. on January 12, 2018. by guest www.bloodjournal.org From almost entirely its extracellular domain, has been implicated to render CLL unresponsive to BCR-induced apoptosis 28 . Furthermore, a high percentage of malignant cells expressing cell surface CD79b in combination with other phenotype markers has been associated with shortened overall survival in B-CLL patients 29, 30 .
An alternative strategy for the treatment of cancer is the use of T-cell receptor (TCR) gene transfer therapy 31, 32 . T-cells engineered to express TCRs with defined antigenspecificity have already successfully been used in the treatment of solid tumors 33 .
Furthermore, only very low quantities of agonistic peptide-HLA complex are required for TCR triggering and T-cell activation [34] [35] [36] while CAR and antibody-based approaches necessitate greater abundance of the antigen 37 . Therefore, T-cells modified with CD79btargeting TCRs can be a valuable addition to current immunotherapies.
T-cells expressing high affinity TCRs recognizing self-antigens such as CD79b in the context of self-HLA molecules are deleted from the naïve T-cell repertoire during thymic development by negative selection to prevent auto-reactivity. In contrast, presentation of such self-antigens in the context of allogeneic HLA (alloHLA) can result in strong T-cell responses as observed in the induction of PRAME-specific T-cells after HLA-A*0201mismatched hematopoietic stem cell transplantation 38 . In an additional study we demonstrated that the high affinity TCRs of these alloHLA-restricted T-cells are singlepeptide specific 39 . Using the concept of self-antigen presented in alloHLA, Wilms tumor antigen (WT1) reactive T-cells have been generated by stimulating T-cells from HLA-A2negative donors with autologous B-lymphocytes coated with HLA-A2 monomers loaded with WT1-derived peptide 40 . Additionally, antigen-specific T-cells were obtained by stimulating T-cells from HLA-A2-negative donors with autologous dendritic cells (DCs) pulsed with RNA to express HLA-A2 in parallel with a variety of targeted antigens [41] [42] [43] .
In this study, from HLA-A*0201/B*0701-negative healthy individuals we isolated 3 T-cell clones targeting 3 distinct CD79b peptides presented in HLA-A*0201 or HLA-B*0702.
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From CD79b-positive primary CLL, ALL and ALL cell lines were recognized by these T-cell clones while no reactivity towards non-hematopoietic tissue was detected. However, low to intermediate recognition of CD14 + monocytes, T-cells and CD34 + hematopoietic precursor cells (HPCs) could be observed. Although no cell surface CD79b was present on these cells, aberrant mRNA expression of CD79b could be detected in these cells.
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Materials and methods

Culture conditions and cells
Generation of peptide-MHC complexes
All peptides were synthesized in-house using standard Fmoc chemistry. Recombinant HLA-A2 and HLA-B7 heavy chain and human β 2 m light chain were in-house produced in Escherichia coli. Major histocompatibility complex (MHC) class I refolding was performed as previously described with minor modifications 44 . MHC class I complexes were purified by gel-filtration using HPLC. pMHC-tetramers were generated by labeling biotinylated pMHC-monomers with streptavidine-coupled phycoerythrin (PE, Invitrogen, Carlsbad, CA, USA) or Quantum dots (Qdots, Invitrogen) Q585, Q605, Q655 and Q705.
Complexes were stored at 4 °C and spun at 17,000 g for 2 min prior to use.
Isolation of CD79b-specific T-cell clones using pMHC-tetramer
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From T-cells binding to pMHC-tetramer containing CD79b peptides were isolated from cryopreserved PBMCs from healthy HLA-A*02:01 and HLA-B*07:02-negative individuals following a previously described protocol 45 Cell-sorting was performed on a FACSAria III (BD Biosciences, San Jose, CA, USA).
FACS analysis
FACS was performed on a LSRII (BD Biosciences) and analyzed using Diva Software (BD Biosciences) or on a FACS Calibur (BD Biosciences) and analyzed using FlowJo Software (TreeStar, Ashland, OR, USA). T-cell lines generated by MACS enrichment using pMHC-tetramers, and T-cell clones were analyzed for pMHC-tetramer + CD8 + Tcells by staining with pMHC-tetramers CD79b 173 :A2 labeled with PE or Q705, CD79b 20 :A2 labeled with Q705 or Q655, CD79b 9 :B7 labeled with Q605 or Q585, and an For personal use only. on January 12, 2018. by guest www.bloodjournal.org From Alexa700-conjugated antibody against CD8 (Invitrogen/Caltag) combined with FITClabelled antibodies against CD4, CD14, and CD19 (BD Pharmingen). Cells were first incubated with a mixture of pMHC-tetramers (0.2 µg/ml per pMHC-tetramer) for 15 min at 37 °C before antibodies were added and incubated for an additional 15 min at 4 °C.
PBMCs, purified hematopoietic cell subsets or activated cells were stained with antibodies against CD79b (BD Pharmingen, clone 3A2-2E7) or isotype control in combination with CD3, CD4, CD14, CD19, CD34 (BD Pharmingen) or CD271 (NGF-R, Sanbio, Uden, The Netherlands) at 4 °C for 15 min.
Functional Analysis
Stimulator cells were peptide-pulsed at various peptide concentrations for 30 min at 37 °C. Responder T-cells and peptide-pulsed or unloaded stimulator cells were coincubated at various responder to stimulator ratios. After 18 h co-incubation, supernatants were harvested and IFN-γ production was measured by enzyme-linked immunosorbent assay (ELISA, Sanquin Reagents, Amsterdam, The Netherlands).
Cytotoxicity Assay
Adapted from Jedema et al. 46 
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated using the RNAqueous Micro-Kit and Small Scale Kit (Ambion, Life Technologies) for a maximum of 0.5×10 6 and 10×10 6 cells, respectively, following For personal use only. on January 12, 2018. by guest www.bloodjournal.org From
Results
Identification of naturally processed and presented CD79b peptides
To identify MHC-presented CD79b peptides we adapted a previously described algorithm 45 . From a peptide elution library that was generated by eluting and sequencing MHC-bound peptides from human HLA-A2/B7-positive B-LCLs 47 , three peptides of CD79b were identified with mascot ion scores above 35 and netMHC 48, 49 binding scores lower than 250 nM ( Table 1 ). Peptides CD79b 9 and CD79b 173 were newly identified.
Peptide CD79b 20 had previously been eluted 50, 51 . All 3 peptides are encoded by each isoform of CD79b. Matching mass spectrometry (MS) fragmentation patterns of eluted and newly synthesized CD79b peptides verified correct identification (data not shown).
Stable pMHC-tetramers of CD79b 20 and CD79b 173 bound to HLA-A2 (CD79b 20 :A2 and CD79b 173 :A2, respectively) and CD79b 9 bound to HLA-B7 (CD79b 9 :B7) were generated by conjugating conventionally refolded pMHC-monomers to streptavidine-labeled fluorophores.
Generation of pMHC-tetramer + CD8 + T-cell lines by tetramer-guided enrichment
T-cells binding to pMHC-tetramers containing CD79b peptides presented in HLA-A2 or HLA-B7 were isolated from PBMCs of 13 HLA-A2/B7-negative healthy individuals using PE-labeled pMHC-tetramers and MACS isolation. From 6×10 7 to 3×10 8 total PBMCs between 10,000-160,000 total cells were recovered in the pMHC-tetramer labeled fraction. Among the isolated cells, 7-21 % were CD8 + T-cells of which only a fraction stained positive for the pMHC-tetramers (data not shown). Other cells included CD4 + Tcells, monocytes and B-cells. After two weeks of expansion, the generated T-cell lines were subjected to a second enrichment using the same pMHC-tetramers. Following two For personal use only. on January 12, 2018. by guest www.bloodjournal.org From weeks of expansion, the presence of CD79b-reactive T-cells were determined by pMHCtetramer staining ( Supplementary Table S1 ; Supplementary Figure S1 ). In In summary, CD8 + T-cells binding to pMHC-tetramers presenting CD79b peptides in HLA-A2 or HLA-B7 could be isolated from the allo-repertoire of HLA-A2/B7-negative individuals. Specificity for their cognate pMHC-tetramers was confirmed for clones K308, S100 and A23 by FACS analysis (Figure 1J-L) . None of the T-cell clones stained with the control pMHC-tetramer composed of HLA-A2 presenting peptide FTWEGLYNV derived from USP11.
Identification of three distinct T-cell clones recognizing CD79b peptides presented in alloHLA
These data demonstrate that we have isolated high avidity peptide-specific T-cell clones targeting CD79b peptides presented by alloHLA molecules. T-cell clones K308, S100, and A23 were identified as the most avid clones targeting peptides CD79b 173 , CD79b 20 , and CD79b 9 , respectively.
CD79b transduction and CD79b knockdown verified CD79b specificity of the T-cell clones
To verify CD79b-dependent reactivity by T-cell clones K308, S100, and A23, K562-A2 and K562-B7 cells were retrovirally transduced with CD79b. Clone K308 and S100 specific for HLA-A2-presented peptides CD79b 173 and CD79b 20 , respectively, demonstrated efficient recognition of K562-A2 engineered to express CD79b, whereas reactivity towards non-transduced K562-A2 or K562 carrying the wrong HLA-restriction molecule was absent (Figure 2A ). CD79b 9 -specific clone A23 efficiently recognized K562 simultaneously expressing HLA-B7 and CD79b, whereas no recognition was observed of non-transduced K562-B7. Recognition was also absent when HLA-A2 was expressed in CD79b-transduced K562 instead of HLA-B7.
Furthermore, downregulation of CD79b with specific shRNA abrogated recognition of CD40L-stimulated CD19 + B-cells from HLA-A2 + healthy individuals by clones K308 and S100 whereas the reactivity of control clone HSS12 specific for a peptide derived from the ubiquitously expressed gene USP11 presented in HLA-A2 was unaffected 39 ( Figure   2B ). Similar results were obtained for clone A23 were CD79b-specific knockdown abrogated recognition of LCL-JY (Supplementary Figure S2) . In summary, CD79bdependent and specific recognition was confirmed for T-cell clones K308, S100, and A23.
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CD79b-specific T-cell clones recognize B-cell malignancies
Next, CD79b-specific T-cell clones K308 and S100 were assessed for their potency to recognize a variety of primary B-cell malignancies and malignant B-cell lines. Clones K308 and S100 efficiently recognized HLA-A2-positive ALL cell lines ( Figure 3A ). Clone S100 also recognized 4 HLA-A2-positive primary CLL samples ( Figure 3B ). In addition, stimulation with primary HLA-A2-positive CLLs and ALLs samples resulted in strong IFNγ production of clone K308 ( Figure 3C 
No reactivity against non-hematopoietic tissue, but unexpected reactivity against different hematopoietic cell subsets
To further validate that the recognition pattern of the CD79b-specific T-cell clones is restricted to the B-cell compartment, their reactivity towards healthy non-hematopoietic and hematopoietic cells was assessed. No IFN-γ production was measured for K308 and S100 after overnight co-culture with HLA-A2-positive fibroblasts or proximal tubular epithelial cells (PTECs) ( Figure 4A ). Recognition was also absent when fibroblast and PTECs were pretreated with IFN-γ for 4 days to simulate inflamed conditions. Control clone HSS12 recognized fibroblasts and PTECs under all conditions indicating the For personal use only. on January 12, 2018. by guest www.bloodjournal.org From stimulatory capacity of the target cells. In addition, we assessed clone K308's reactivity towards hematopoietic cell populations by isolating different cell subsets from peripheral blood of HLA-A2-positive healthy individuals. As shown in Figure 4B , clone K308 did not recognize monocyte-derived immature and mature DCs. However, clone K308 exhibited intermediate reactivity against either activated or non-activated CD4 + T-cells, nonactivated CD8 + T-cells and CD34 + HPCs as well as low reactivity against CD14 + monocytes ( Figure 4B-D) . Furthermore, co-incubation of non-activated and activated Bcells and T-cells, and CD34 + HPCs with clone K308 also led to their lysis which was not observed when target cells were co-incubated with a CMV-specific T-cell clone ( Figure   4E -F). Similarly, clone S100 also recognized activated CD4 + T-cells ( Figure 4G ).
Aberrant CD79b expression in T-cells, HPCs and monocytes is responsible for reactivity of CD79b-specific T-cell clones
To resolve the unexpected recognition of T-cells, HPCs, and monocytes, we examined whether these cell populations demonstrated unreported CD79b cell-surface expression.
Staining of PBMCs with anti-CD79b antibody revealed no cell-surface expression of
CD79b on CD3 + T-cells and CD14 + monocytes ( Figure 5A 
In summary, aberrant gene expression of CD79b in CD4 + T-cells, HPCs and monocytes
although undetectable at the cell-surface, caused unexpected reactivity of the CD79bspecific T-cell clones against these cell-subsets.
Discussion
In this study, we aimed to isolate T-cells expressing TCRs specific for BCR associated protein CD79b that is expressed on normal and malignant B-cells [14] [15] [16] . MHC-presented peptides of CD79b were identified from peptide elution studies 47, 50, 51 The high-avidity CD79b-specific T-cells recognizing a self-antigen such as CD79b when presented in HLA-A2 or HLA-B7 were isolated from HLA-A2/B7-negative individuals.
Negative selection during thymic development does not deplete these high-avidity Tcells in these individuals since the HLA-A2 and HLA-B7 restriction molecules are not present. In HLA-A2 and HLA-B7-positive individuals, however, the elimination of such
high-avidity CD79b-specific T-cells is crucial to prevent loss of B-cells, monocytes, and
HPCs due to auto-reactivity. Furthermore, the CD79b expression in HLA-A2/B7-positive T-cells would also cause fratricide 41 
among T-cells; T-cells would simultaneously
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From page 22 express the correct HLA restriction molecule as well as the CD79b antigen recognized by their TCR. In concordance, we have previously shown that self-HLA-restricted PRAME-specific T-cells possess insufficient avidity to recognize endogenously expressed PRAME 38 . Therefore, it is very unlikely that such high-avidity CD79b-specific T-cells as demonstrated in this study could be isolated from the autologous repertoire of HLA-A2 and HLA-B7 individuals.
In conclusion, exploiting the immunogenicity of alloHLA molecules is an effective and attractive strategy to overcome self-tolerance towards self-antigens. TCRs raised from alloreactive T-cells can meet the requirements for high affinity interaction with selfantigens while preserving peptide specificity and HLA-restriction. Their identification can be readily achieved by pMHC-tetramer based isolation but requires functional assessment on a clonal level. Aberrant expression of CD79b in monocytes, T-cells and HPCs eliminated CD79b as a suitable target for TCR-based immunotherapy to treat Bcell malignancies. However, CD79b may still be an attractive target for CAR or antibodybased immunotherapies since no cell-surface expression on monocytes, T-cells and HPCs was observed.
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From 48, 49 For personal use only. on January 12, 2018. by guest www.bloodjournal.org From CD79b-negative K562-A2 or K562-B7 cells were included as controls. IFN-γ secretion was measured using standard ELISA. Axes were adjusted to maximum cytokine release measured. (J-L) K308 was stained with pMHC-tetramer CD79b 173 :A2 (J), S100 with CD79b 20 :A2 (K) and A23 with CD79b 9 :B7 (L). Staining with an irrelevant pMHC-tetramer USP11:A2 was used as control. Dot plots are shown with bi-exponential axis.
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From UHK CD19 + ) were transduced with CD79b-specific shRNA (shRNA) and selected by puromycine treatment or left untreated (nt) and co-incubated with T-cell clones K308, S100 or control clone HSS12. Clone K308 and S100 were co-cultured at stimulator to responder (S:R) ratio of 2:1. Control clone HSS was co-cultured at an S:R ration of 10:1.
IFN-γ production was determined using standard ELISA. Antigen-presenting capacity of transduced and non-transduced target cells was controlled by clone HSS12.
For personal use only. on January 12, 2018. by guest www.bloodjournal.org From were CD14 + monocyte derived (see "Supplementary data"). Activated CD4 + were generated from CD4 + cells that were treated with 0.8 ng/ml PHA and cultured for 10 days. Non-activated CD19 + , CD14 + , CD4 + and CD34 + cells were isolated from peripheral blood using MACS isolation. (D) Clone K308 was stimulated with primary CD4 + or CD8 + cells in a S:R ration of 6:1. (E and F) Cytotoxicity of clone K308 was determined for nonactivated CD4 and CD8 T cells and activated T cells (containing CD4 and CD8), and activated and non-activated CD19 B-cells (E), and CD34 + HPCs (F). PKH26GL-labelled target cells were co-incubated with K308 (K308) at different effector to target ratios for Figure 5 
